Tirzepatide (Injectable) in Louisiana
Doctor-prescribed Tirzepatide (Injectable) for Louisiana residents. Reviewed by licensed Louisiana physicians, compounded at FDA-registered pharmacies, and shipped to your door.
All-in monthly price
No membership fee · this is the full price · free shipping · avg 4-week supply
Add in-depth bloodwork
Optional — add a physician-reviewed at-home blood panel to your plan.
Your sex-hormone baseline plus the safety markers that matter on therapy — blood counts, liver and kidney function — from one painless upper-arm device. Matched to your sex (PSA for men; progesterone & FSH for women). No needle, no clinic, physician-reviewed.
This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.

Reviewed by Dr. Gene, MD · Board-certified Family Medicine
Every Pepti prescription is reviewed by a licensed U.S. physician before it's dispensed — and only provided if clinically appropriate.
How it works in Louisiana
- 1Complete a free online intake (~5 minutes).
- 2A licensed Louisiana physician reviews your case within 24 hours.
- 3Your prescription ships from our FDA-registered compounding pharmacy.
- 4Free shipping arrives 2–4 business days later. Refills ship automatically when your supply runs out — cancel anytime.
What Tirzepatide (Injectable) does
Dual GIP and GLP-1 receptor agonist offering enhanced weight management benefits.
Strength is compounded to the exact dose your physician prescribes and stepped up over time; paired with B6 to ease nausea.
Amounts shown are per unit. Compounded fresh at a US FDA-registered pharmacy.
Quality
Every batch independently tested
Every medication batch dispensed through Pepti is independently tested by a qualified third-party laboratory for applicable quality and safety standards before the pharmacy releases it. Batches are tested to the same standard used by 503B outsourcing facilities.
Sterility
USP <71>Confirms the finished preparation is free of viable microorganisms.
Bacterial endotoxins
USP <85>Screens for endotoxins that can cause fever or inflammatory reactions.
Potency
AssayVerifies the labeled concentration of the active peptide is what is in the vial.
Purity
HPLCChecks the active peptide against impurities and degradation products.
Identity
Mass spectrometryConfirms the peptide in the vial is the correct molecule.
pH
USP <791>Confirms the solution sits within the range specified for injection.
Particulate matter
USP <788>Checks the finished vial for visible and sub-visible particles.
Container closure integrity
USP <1207>Confirms the vial seal holds so sterility is maintained through the beyond-use date.
Recent lots
- Lot 100526-TIR-10
Tested 2026-10-07 · Biolink Life Sciences Carolinas
Sterility
Sterile
Endotoxin
<2 EU/mL
Potency
99.2%
- Lot 100526-TIR-20
Tested 2026-10-07 · Biolink Life Sciences Carolinas
Sterility
Sterile
Endotoxin
<2 EU/mL
Potency
100.2%
- Lot 100526-TIR-30
Tested 2026-10-07 · Biolink Life Sciences Carolinas
Sterility
Sterile
Endotoxin
<2 EU/mL
Potency
99.4%
Telemedicine in Louisiana.
Louisiana permits telemedicine prescribing under Louisiana State Board of Medical Examiners telemedicine rules. A Louisiana-licensed physician can establish the patient relationship through online intake review — no in-person visit is required for non-controlled medications. Pepti is available in all 50 states and Washington, D.C.
Louisiana is among the states with the highest adult obesity prevalence, driving strong demand for GLP-1 and metabolic peptide therapy via telehealth.
Louisiana cities Pepti serves
+ 1 more cities
, New IberiaWeight management in Louisiana
The CDC reports 35%+ (CDC 2023) adult obesity prevalence in Louisiana, well above the threshold where GLP-1 therapy demonstrates significant clinical benefit. Tirzepatide (Injectable) is prescribed in Louisiana when BMI thresholds and intake criteria are met under physician review.
Your protocol
How Tirzepatide is prescribed in Louisiana.
Who it's for
- Adults with a BMI in the range their physician considers appropriate for dual GIP/GLP-1 therapy
- Patients who did not reach their goal on semaglutide
- People who want physician-managed dose escalation rather than a fixed dose
- Patients already on tirzepatide who want to continue at their current dose
Your physician decides whether Tirzepatide is appropriate for you after reviewing your intake and labs.
Directions & duration
Inject 0.50 mL (50 units) subcutaneously once weekly.
What's included
- Licensed physician review of your intake, history, and labs
- Medication compounded to your prescription by a PCAB-accredited, FDA-registered pharmacy
- Every batch independently tested before release
- Sterile syringes and alcohol prep pads for injectables
- Tracked delivery to your door, refills on schedule
- Message your physician anytime; dose changes without an appointment
Storage & handling
- Store refrigerated (36–46°F / 2–8°C) at all times, including before first use.
- One vial is your monthly supply. A fresh vial ships to your Louisiana address every 28 days on your refill schedule, so you're always well inside the beyond-use date on your label.
- Protect from light. Wipe the stopper with an alcohol pad before every draw.
- Dispose of syringes in the sharps container per the included instructions.
What to expect
A typical course of Tirzepatide in Louisiana.
The science
How Tirzepatide works, and what the research shows.
How it works
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both incretin pathways instead of just one.
This dual action produces superior weight loss results vs semaglutide alone.
Phase 3 trials showed up to 22.5% body weight loss.
Clinical evidence
The SURMOUNT-1 trial randomized 2,539 adults with obesity to tirzepatide 5/10/15 mg vs placebo.
Jastreboff et al., NEJM 2022At 72 weeks, mean weight reductions were 15.0%, 19.5%, and 20.9% on the active arms vs 3.1% on placebo — the highest weight-loss outcomes recorded for a pharmacological intervention at the time.
SURMOUNT-2 confirmed efficacy in patients with type 2 diabetes, and the SURPASS program demonstrated superior HbA1c reduction vs semaglutide head-to-head.
Frias et al., 2021Tirzepatide's dual GIP+GLP-1 mechanism appears to drive both stronger appetite suppression and improved metabolic flexibility.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine (2022) · PMID 35658024
- Garvey WT, Frias JP, Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) · Lancet (2023) · PMID 37385275
- Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) · New England Journal of Medicine (2021) · PMID 34170647
- Inagaki N, Takeuchi M, Oura T, et al.. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial · The Lancet Diabetes & Endocrinology (2022) · PMID 35468322
- Malhotra A, Grunstein RR, Fietze I, et al.. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) · New England Journal of Medicine (2024) · PMID 38912654
- Nicholls SJ, Pavo I, Bhatt DL, et al.. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) · New England Journal of Medicine (2025) · PMID 41406444
- Aronne LJ, Sattar N, Horn DB, et al.. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial · JAMA (2024) · PMID 38078870
- Pasternak B, Wintzell V, Hviid A et al.. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study · BMJ (2024) · PMID 38683947
- Quddos F, Hubshman Z, Tegge A, et al.. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity · Scientific Reports (2023) · PMID 38017205
- Drummond RF, Seif KE, Reece EA. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review · Am J Obstet Gynecol (2025) · PMID 39181497
- Wang S, Sun J, Wang J, et al.. Does obesity based on body mass index affect semen quality? A meta-analysis and systematic review from the general population rather than the infertile population · Andrologia (2021) · PMID 34028074
- Urva S, Coskun T, Loghin C, et al.. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists · Diabetes, Obesity and Metabolism (2020) · PMID 32519795
- Borner T, Geisler CE, Fortin SM, et al.. GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models · Diabetes (2021) · PMID 34380697
- Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment · N Engl J Med (2001) · PMID 11372012
- Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it · Int J Epidemiol (2005) · PMID 15333621
- McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects · J Clin Epidemiol (2014) · PMID 24275499
- Heise T, DeVries JH, Urva S, et al.. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes · Diabetes Care (2023) · PMID 36857477
- Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide · CPT Pharmacometrics Syst Pharmacol (2024) · PMID 38356317
- Bochanen N, Decochez K, Heleu E, Cuypers J, et al.. Lipohypertrophy Monitoring Study (LIMO): Effect of single use of 4 mm pen needles combined with education on injection site rotation on glycaemic control: Confirmation of an unpleasant truth · Diabet Med (2022) · PMID 34407260
- Murao S, Murao K, Nagata T, Shimizu M. Repeated insulin injection without site rotation affects skin thickness - ultrasonographic and histological evaluation · J Diabetes Investig (2022) · PMID 35060349
- Deng N, Zhang X, Zhao F, Wang Y. Prevalence of lipohypertrophy in insulin-treated diabetes patients: A systematic review and meta-analysis · J Diabetes Investig (2017) · PMID 28862814
- Wadden TA, Chao AM, Machineni S, et al.. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial · Nature Medicine (2023) · PMID 37840095
- Rosenstock J, Wysham C, Frías JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial · Lancet (2021) · PMID 34186022
- Ludvik B, Giorgino F, Jódar E, et al.. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial · Lancet (2021) · PMID 34370970
- Del Prato S, Kahn SE, Pavo I, et al.. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial · Lancet (2021) · PMID 34672967
- Dahl D, Onishi Y, Norwood P, et al.. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial · JAMA (2022) · PMID 35133415
- Guo L, Klonoff DC, Al Sifri SN, Bee YM et al.. Consensus Recommendations on Lipohypertrophy: Insights From an International Panel of Experts · Diabetes Research and Clinical Practice (2026) · PMID 42398590
- Sattar N, Linetzky B, Ruotolo G et al.. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis · J Am Coll Cardiol (2026) · PMID 42233927
- Coskun T, Sloop KW, Loghin C, et al.. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept · Molecular Metabolism (2018) · PMID 30473097
- Sattar N, McGuire DK, Pavo I, et al.. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis · Nature Medicine (2022) · PMID 35210595
- Samms RJ, Coghlan MP, Sloop KW. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity · Diabetes (2025) · PMID 40521890
- Wang L, Wang N, Zhang W et al.. Therapeutic peptides: current applications and future directions · Signal Transduct Target Ther (2022) · PMID 35165272
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
PCAB-accredited pharmacies on every order.
Every fulfillment runs through a PCAB-accredited pharmacy.
See the lab results
- Rigorous third-party quality & safety inspections
- Cleanliness and sterile processes
- Proper ingredient sourcing
- Accurate dosing and formulation
- Staff training and procedures
- Accredited by NABP & ACHC
Frequently asked
about Tirzepatide (Injectable) in Louisiana.
Yes. Tirzepatide (Injectable) is legal when prescribed by a physician licensed in Louisiana and dispensed by an FDA-registered compounding pharmacy. Louisiana permits telemedicine prescribing under Louisiana State Board of Medical Examiners telemedicine rules. A Louisiana-licensed physician can establish the patient relationship through online intake review — no in-person visit is required for non-controlled medications.
Most orders ship from our FDA-registered compounding pharmacy within 1–3 business days after physician approval. Delivery within Louisiana typically arrives 1-3 business days after shipment. Pepti serves patients across Louisiana including New Orleans, Baton Rouge, Shreveport, and Lafayette.
No. Pepti operates as a fully telehealth platform in Louisiana. Louisiana permits telemedicine prescribing under Louisiana State Board of Medical Examiners telemedicine rules. A Louisiana-licensed physician can establish the patient relationship through online intake review — no in-person visit is required for non-controlled medications.
Tirzepatide (Injectable) starts at $159 at Pepti. Pepti is subscription-based — your refill ships when your supply runs out, and you can cancel anytime. Pricing is the same nationwide — no Louisiana-specific markup. Shipping is free.
Yes — Pepti is available in all 50 states and Washington, D.C. Wherever you are in the country, a physician licensed in your state reviews your intake and your medication ships from an FDA-registered compounding pharmacy.
You don't need an in-person peptide clinic — Pepti provides doctor-prescribed Tirzepatide (Injectable) entirely online anywhere in Louisiana. A physician licensed in Louisiana reviews your intake, and your medication ships from an FDA-registered compounding pharmacy to your door. Unlike "research use only" peptide sites, every Pepti order requires a valid patient-specific prescription and a licensed dispensing pharmacy.
No. "Research use only" Tirzepatide (Injectable) is sold with no prescription, no physician, and no dispensing pharmacy, and is not legally sold for human use — independent testing of research-grade peptides has repeatedly found underdosing, mislabeling, and contamination. Prescription Tirzepatide (Injectable) is compounded for you at an FDA-registered US pharmacy after a licensed physician's review. When comparing Tirzepatide (Injectable) options in Louisiana, only consider providers that can name their prescribing physicians and their dispensing pharmacy.
The CDC reports an adult obesity prevalence of 35%+ (CDC 2023) in Louisiana. GLP-1 therapy is increasingly the standard of care for sustained weight loss in patients with BMI ≥ 30 or BMI ≥ 27 with weight-related comorbidities. Tirzepatide (Injectable) is prescribed in Louisiana via Pepti when clinically appropriate.
33 more questions about Pepti, answered.Show fewer
Pepti serves all of Louisiana. A physician licensed in Louisiana reviews every order within 4 hours, the prescription is compounded by a state-licensed, FDA-registered pharmacy, and it ships free and tracked to any Louisiana street address. The price is the same as every other state.
Yes. The whole process is online in Louisiana: a free assessment, physician review, messaging, dose changes, and refills through your Pepti account or the Hello Pepti app. No clinic visit is required.
Pepti ships Tirzepatide to Louisiana directly from the pharmacy: free, tracked, unbranded, in insulated packaging with ice packs for refrigerated medication. The pharmacy compounds in 1-3 business days and delivery takes 1-3 business days after shipment. PO Boxes are not accepted.
Every treatment on Pepti's catalog ships to Louisiana. Eligibility is confirmed during the assessment from your Louisiana shipping address, and if anything ever cannot ship to your address it is refunded.
The same as everywhere Pepti serves: one all-in monthly price per treatment that includes the medication, the physician, and shipping, with no Louisiana-specific markup and no membership or consult fee. Every price is on the product page.
Yes. Pepti's physicians hold licenses in Louisiana, and only a physician licensed where you live reviews and prescribes your order. Their names and credentials are on the providers page.
Yes. Pepti's partner pharmacies are state-licensed, FDA-registered 503A compounding pharmacies licensed to dispense into Louisiana, and every batch is independently tested before it ships.
Dual GIP and GLP-1 receptor agonist offering enhanced weight management benefits. Tirzepatide is prescription-only at Pepti: a licensed physician reviews your assessment and, if appropriate, prescribes it to be compounded by a state-licensed, FDA-registered pharmacy.
Tirzepatide is commonly prescribed for: Adults with a BMI in the range their physician considers appropriate for dual GIP/GLP-1 therapy; Patients who did not reach their goal on semaglutide; People who want physician-managed dose escalation rather than a fixed dose; Patients already on tirzepatide who want to continue at their current dose. Whether it is appropriate for you is decided by the reviewing physician from your history, medications, and labs where required.
Yes. Tirzepatide is prescription-only. The free online assessment takes about five minutes, a physician licensed in Louisiana reviews it within 4 hours, and if approved the prescription goes to the pharmacy. If not approved, the medication charge is refunded.
Yes. Tirzepatide is one of the medications Pepti requires recent bloodwork for before it is prescribed. Upload a recent lab report from any lab, or order Pepti's at-home panel; the physician reviews the results with your assessment.
Tirzepatide is a subcutaneous injection into the abdomen or thigh with a small insulin syringe. Your kit ships with sterile syringes and alcohol prep pads, and the exact dose and schedule are printed on the pharmacy label. Dosing videos are in your account.
One vial is your monthly supply at the dose your physician prescribes. A fresh vial ships about every 28 days, and the date moves if your physician changes your dose. Store it as the pharmacy label directs, refrigerated.
Once per fill, $159 each time, when the next vial ships. It renews until you cancel, which you can do anytime from your account with no cancellation fee.
The compounded Tirzepatide with sterile syringes and alcohol prep pads, free tracked shipping in an unbranded box with insulated packaging, the physician review, ongoing physician care and dose adjustments, and unlimited messaging.
Reported side effects of Tirzepatide are usually mild: nausea; diarrhea or constipation; fatigue; reduced appetite; heartburn. The physician screens your history, medications, and allergies before prescribing, the medication-specific consent lists the known risks, and you can message your physician about anything you notice. Seek emergency care for severe symptoms.
Response varies by person, goal, and dose, and Tirzepatide is prescribed for ongoing use rather than a short trial. Your physician sets expectations at approval, tracks how you respond through your account, and adjusts the dose without an appointment.
Yes, one step at a time. Tirzepatide moves up the pharmacy's strength ladder when your physician approves, and you pay the cost difference for the higher strength. It is never doubled.
Yes. Add Tirzepatide to a plan with another treatment and both go through one assessment and one physician review, shipping together on one schedule. Each keeps its own catalog price. The physician reviews the combination and can adjust it.
Compounded Tirzepatide is not FDA-approved. A brand-name form of the active ingredient is FDA-approved for specific indications; Pepti's version is compounded to your physician's prescription by an FDA-registered 503A pharmacy and prescribed off-label.
Yes, when prescribed by a licensed physician and dispensed by a licensed pharmacy, which is how Pepti provides it in Louisiana. Research-use-only Tirzepatide sold without a prescription is labeled not for human use and is a different product.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both incretin pathways instead of just one. At Pepti it is prescribed to support dual gip/glp-1 action, superior weight loss, metabolic health, appetite reduction. Individual response varies, and your physician sets expectations at approval.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both incretin pathways instead of just one. This dual action produces superior weight loss results vs semaglutide alone. Phase 3 trials showed up to 22.5% body weight loss. Compounded Tirzepatide is not FDA-approved; it is prescribed off-label by a licensed physician after reviewing your assessment.
Tirzepatide is prescribed for dual gip/glp-1 action, superior weight loss, metabolic health, appetite reduction. It is commonly requested by adults with a BMI in the range their physician considers appropriate for dual GIP/GLP-1 therapy; patients who did not reach their goal on semaglutide; people who want physician-managed dose escalation rather than a fixed dose; patients already on tirzepatide who want to continue at their current dose. Whether it is appropriate for you is the reviewing physician's decision.
Tirzepatide is studied for dual gip/glp-1 action, superior weight loss, metabolic health, appetite reduction. Those are the goals it is prescribed to support at Pepti; results vary by person, dose, and consistency, and no outcome is guaranteed. Your physician tracks how you respond through your account.
The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) randomized 2,539 adults with obesity to tirzepatide 5/10/15 mg vs placebo. At 72 weeks, mean weight reductions were 15.0%, 19.5%, and 20.9% on the active arms vs 3.1% on placebo — the highest weight-loss outcomes recorded for a pharmacological intervention at the time. SURMOUNT-2 confirmed efficacy in patients with type 2 diabetes, and the SURPASS program (Frias et al., 2021) demonstrated superior HbA1c reduction vs semaglutide head-to-head. Tirzepatide's dual GIP+GLP-1 mechanism appears to drive both stronger appetite suppression and improved metabolic flexibility. References are listed on this page.
Tirzepatide is generally not prescribed with: active cancer or history of cancer (unless approved by oncologist); pregnancy or breastfeeding; severe kidney or liver disease; known allergy to the peptide or excipients; medullary thyroid cancer history; men 2 syndrome. The physician screens for these in your intake, and anything that rules Tirzepatide out means it is not prescribed and is refunded.
At Pepti. Complete the free assessment, a physician licensed in Louisiana reviews it within 4 hours, and if appropriate Tirzepatide is compounded by a state-licensed, FDA-registered pharmacy and shipped free to your door for $159 per month, all-in. Not prescribed means refunded.
Injectable vial: 2 mL, containing compounded to your dose Tirzepatide + included Cyanocobalamin (B12). One vial is your monthly supply at the prescribed dose, and a fresh one ships about every 28 days.
Not currently. Tirzepatide ships as a multi-dose vial with sterile syringes and prep pads. The pepti Pen is available for 10 other treatments.
$159 per month covers the compounded Tirzepatide, the physician review, ongoing physician care including dose adjustments and refill review, unlimited messaging, and free tracked shipping. There is no membership, consult, visit, or refill fee; the only separate charges are optional at-home lab panels and a physician-approved dose increase billed at pharmacy cost.
Yes. Tirzepatide is on Pepti's live catalog, which lists only treatments a partner pharmacy can compound and ship today. If a physician prescribes it, it ships; if it ever cannot be dispensed, the charge is refunded.
Tirzepatide ships to 50 states, free and tracked, in insulated unbranded packaging. Eligibility is confirmed during the assessment from your shipping address.
Tirzepatide (Injectable) in every state
Pepti is available in all 50 states and Washington, D.C.
Pepti operates in Louisiana through licensed physician partnerships. Compounded medications are produced at FDA-registered 503A pharmacies. Treatment decisions are made by your prescribing physician.
